Clik here to view.
Seattle Genetics Misses 1st Quarter Sales Estimate, But Sees $1B Future
Luke Timmerman Seattle Genetics fell short of Wall Street’s quarterly sales expectations for its new lymphoma drug, but the company boldly declared today that it …
View ArticleClik here to view.
ASCO Preview: Eight Cancer Drugs to Watch at the Big Show
Luke Timmerman The pistons of the biggest publicity engine in cancer R&D will start firing this week. It’s time to behold the annual rite of …
View ArticleClik here to view.
Seattle Genetics Follows the Science, Taking on Rare Lymphoma No. 3
Luke Timmerman Sometimes when a drug hits the market, it can take on a life of its own. Researchers start using their imaginations—and their own …
View ArticleClik here to view.
ASCO Wrap-Up: A Summary of This Week’s Cancer R&D Headlines
Luke Timmerman There’s so much going on in the world of cancer drug R&D that it’s hard to keep up with all the news about drugs that are changing the …
View ArticleClik here to view.
Aerie Pharma Eyes $58M IPO For Glaucoma Drug Push
View the Slideshow Ben Fidler Many investors may be waiting for Ophthtotech to price its coming IPO, but another startup from the Tri-state area developing eye drugs has just …
View ArticleClik here to view.
Regeneron, Sanofi Pass First Key Test With Cholesterol-Lowering Drug
Ben Fidler Scientists who study cardiovascular disease have been buzzing about the promise of a target called PCSK9 for years. The target is also part of a high-stakes race that …
View ArticleClik here to view.
Aerie Gets Lukewarm Reception, Cuts IPO Price to $10 Per Share
Ben Fidler Aerie Pharmaceuticals wanted a $68 million haul when it set the price range for its IPO last week. It came close to that number, but it had to …
View ArticleClik here to view.
Hologic, Fending off Icahn, Adopts Poison Pill to Deflect Takeover
Ben Fidler Billionaire financier and activist investor Carl Icahn has found a new target: Bedford, MA-based Hologic (NASDAQ: HOLX). Icahn today reported a 12.63 percent stake in Hologic, …
View ArticleClik here to view.
Hologic Names New CEO, Cuts Deal With Icahn to Avoid Proxy Fight
View the Slideshow Ben Fidler Apparently, Hologic was in no mood to wage a proxy war with Carl Icahn. Bedford, MA-based Hologic (NASDAQ: HOLX) today shook up its leadership. …
View ArticleClik here to view.
AbbVie Plunks Down $275M Upfront for Infinity’s Blood Cancer Drug
Ben Fidler It’s been a topsy-turvy few years for Infinity Pharmaceuticals. The Cambridge, MA-based company is well behind a few others, whose rival blood cancer drugs that have already made …
View ArticleClik here to view.
As Rival Sputters, FibroGen Heads to Nasdaq Via $146M IPO
Ben Fidler When it comes to raising money from public investors, timing is everything. And it certainly didn’t hurt San Francisco-based FibroGen’s IPO pitch when one of its rivals released (Read more...)
View ArticleClik here to view.
CF Foundation Cashes Out on Kalydeco in $3.3B Sale to Royalty Pharma
Ben Fidler Vertex Pharmaceuticals has developed a drug that has changed the way cystic fibrosis is treated for some patients with a specific genetic mutation. And now the non-profit organization (Read...
View ArticleClik here to view.
BioMarin Gambles $840M on Prosensa’s Duchenne Drug
Ben Fidler It wasn’t too long ago that Prosensa Holding was kicked to the curb by Wall Street investors. Following a failed Phase 3 trial for its Duchenne Muscular Dystrophy (Read more...)
View Article
